Pneumonia in the neutropenic cancer patient

Current Opinion in Pulmonary Medicine

Volumn 21, Issue 3, 2015, Pages 260-271

  Evans, Scott E ^a   Ost, David E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cancer; galactomannan; leukaemia; neutropenia; pneumonia

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; GALACTOMANNAN;

ANTIBIOTIC THERAPY; ATYPICAL MYCOBACTERIUM; CANCER PATIENT; CLINICAL ASSESSMENT; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FUNGUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; INVASIVE ASPERGILLOSIS; LOWER RESPIRATORY TRACT INFECTION; LUNG INFILTRATE; LUNG LAVAGE; MICROBIOLOGICAL EXAMINATION; MOLECULAR DIAGNOSIS; MYCOBACTERIUM; NEUTROPENIA; NEUTROPENIC PNEUMONIA; PATHOGENESIS; PATHOPHYSIOLOGY; PNEUMONIA; PREVALENCE; REVIEW; SCREENING; SENSITIVITY AND SPECIFICITY; VIRUS; YOUDEN INDEX; BLOOD; MICROBIOLOGY; NEOPLASM; PNEUMONIA, BACTERIAL;

HUMANS; NEOPLASMS; NEUTROPENIA; PNEUMONIA, BACTERIAL;

EID: 84926362962     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000156     Document Type: Review

References (131)

1. File TM. Community-acquired pneumonia. Lancet 2003; 362:1991-2001.
2. Joos L, Tamm M. Breakdown of pulmonary host defense in the immunocom-promised host: cancer chemotherapy. Proc Am Thorac Soc 2005; 2:445-448.
3. Mizgerd JP. Lung infection-a public health priority. PLoS Med 2006; 3:e76.
4. WHO. The World Health Report 2004-changing history. Geneva: World Health Organization; 2004.
5. Ahmed S, Siddiqui AK, Rossoff L, et al. Pulmonary complications in chronic lymphocytic leukemia. Cancer 2003; 98:1912-1917.
6. Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin 2001; 17:531-570.
7. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106:2258-2266.
8. Garcia JB, Lei X, Wierda W, et al. Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc 2013; 10:432-440.
9. Rossini F, Verga M, Pioltelli P, et al. Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracy-cline-containing regimens. Haematologica 2000; 85:1255-1260.
10. Specchia G, Pastore D, Carluccio P, et al. Pneumonia in acute leukemia patients during induction therapy: experience in a single institution. Leuk Lymphoma 2003; 44:97-101.
11. Whimbey E, Goodrich J, Bodey GP. Pneumonia in cancer patients. Cancer Treat Res 1995; 79:185-210.
12. Wilhelm M, Kantarjian HM, O'Brien S, et al. Pneumonia during remission induction chemotherapy in patients with AML or MDS. Leukemia 1996; 10:1870-1873.
13. Yoshida M, Akiyama N, Fujita H, et al. Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int J Hematol 2011; 93:66-73.
14. Cannas G, Pautas C, Raffoux E, et al. Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leuk Lymphoma 2012; 53:1068-1076.
15. Lossos IS, Breuer R, Or R, et al. Bacterial pneumonia in recipients of bone marrow transplantation. A five-year prospective study. Transplantation 1995; 60:672-678.
16. Roychowdhury M, Pambuccian SE, Aslan DL, et al. Pulmonary complications after bone marrow transplantation: an autopsy study from a large transplantation center. Arch Pathol Lab Med 2005; 129:366-371.
17. Chang HY, Rodriguez V, Narboni G, et al. Causes of death in adults with acute leukemia. Medicine (Baltimore) 1976; 55:259-268.
18. Chaoui D, Legrand O, Roche N, et al. Incidence and prognostic value of respiratory events in acute leukemia. Leukemia 2004; 18:670-675.
19. Hohenthal U, Itala M, Salonen J, et al. Bronchoalveolar lavage in immuno-compromised patients with haematological malignancy-value of new microbiological methods. Eur J Haematol 2005; 74:203-211.
20. Sharma A, Lokeshwar N. Febrile neutropenia in haematological malignancies. J Postgrad Med 2005; 51 (Suppl 1):S42-S48.
21. Shorr AF, Susla GM, O'Grady NP. Pulmonary infiltrates in the non-HIV-infected immunocompromised patient: etiologies, diagnostic strategies, and outcomes. Chest 2004; 125:260-271.
22. Peckham D, Elliott MW. Pulmonary infiltrates in the immunocompromised: diagnosis and management. Thorax 2002; 57 (Suppl 2):II3-II7.
23. Offidani M, Corvatta L, Malerba L, et al. Infectious complications in adult acute lymphoblastic leukemia (ALL): experience at one single center. Leuk Lymphoma 2004; 45:1617-1621.
24. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328-340.
25. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:427-431.
26. Meyer E, Beyersmann J, Bertz H, et al. Risk factor analysis of blood stream infection and pneumonia in neutropenic patients after peripheral blood stem-cell transplantation. Bone Marrow Transplant 2007; 39:173-178.
27. Lanoix JP, Schmit JL, Douadi Y. Bacterial lung sepsis in patients with febrile neutropenia. Curr Opin Pulmon Med 2012; 18:175-180.
28. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neu-tropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003; 98:2402-2409.
29. Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003; 44:2069-2076.
30. Lynn JJ, Chen KF, Weng YM, Chiu TF. Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department. Hematol Oncol 2013; 31:189-196.
31. Hubel K, Hegener K, Schnell R, et al. Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann Hematol 1999; 78:73-77.
32. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2):S27-S72.
33. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754.
34. British Thoracic Society Standards of Care Committee. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax2001; 56 (Suppl 4):IV1-IV64.
35. Gonzalez C, Johnson T, Rolston K, et al. Predicting pneumonia mortality using CURB-65, PSI, and patient characteristics in patients presenting to the emergency department of a comprehensive cancer center. Cancer Med 2014; 3:962-970.
36. Bartlett JG. Community-acquired pneumonia. Int J Clin Pract Suppl 2000; 115:18-22.
37. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347-382.
38. Aisenberg G, Rolston KV, Safdar A. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer 2004; 101:2134-2140.
39. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007; 45:1602-1609.
40. Klastersky J, Aoun M. Opportunistic infections in patients with cancer. Ann Oncol 2004; 15 (Suppl 4):iv329-iv335.
41. Maschmeyer G, Carratala J, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 2015; 26:21-33.
42. Einsele H, Bertz H, Beyer J, et al. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 (Suppl 2):S175-S185.
43. Gudiol C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutro-penic cancer patients. Clin Microbiol Infect 2013; 19:474-479.
44. Marchetti O, Calandra T. Infections in neutropenic cancer patients. Lancet 2002; 359:723-725.
45. Maschmeyer G. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic cancer patients. Curr Infect Dis Rep 2011; 13:510-516.
46. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-1433.
47. American Thoracic Society; Infectious Diseases Society of America. Guide-lines for the management of adults with hospital-acquired, ventilator-asso ciated, and healthcare-associated pneumonia. Am J Respir Crit Care, Med 2005; 171:388-416.
48. El-Solh AA, Aquilina AT, Dhillon RS, et al. Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older people with severe pneumonia. Am J Respir Crit Care Med 2002; 166:1038-1043.
49. Araoka H, Fujii T, Izutsu K, et al. Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy. Transplant Infect Dis 2012; 14:355-363.
50. Duncan MD, Wilkes DS. Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections. Proc Am Thorac Soc 2005; 2:449-455.
51. Yadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 2003; 37:1144-1145.
52. Mori M, Tsunemine H, Imada K, et al. Life-threatening hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in the treatment of hema-tologic diseases. Ann Hematol 2014; 93:901-911.
53. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122:2115-2121.
54. Harrington RD, Woolfrey AE, Bowden R, et al. Legionellosis inabone marrow transplant center. Bone Marrow Transplant 1996; 18:361-368.
55. Kugler JW, Armitage JO, Helms CM, et al. Nosocomial Legionnaires' disease. Occurrence in recipients of bone marrow transplants. Am J Med 1983; 74:281-288.
56. Torres HA, Reddy BT, Raad II, et al. Nocardiosis in cancer patients. Medicine (Baltimore) 2002; 81:388-397.
57. Hachem RY, Kontoyiannis DP, Boktour MR, et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with he-matologic malignancies. Cancer 2004; 101:1594-1600.
58. Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183:96-128.
59. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358-4366.
60. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-917.
61. Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16:875-894; vi.
62. Mulanovich VE, Kontoyiannis DP. Fungal pneumonia in patients with hema-tologic malignancies: current approach and management. Curr Opin Infect Dis 2011; 24:323-332.
63. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-1360.
64. Roblot F, Le Moal G, Godet C, et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J Infect 2003; 47:19-27.
65. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350:2487-2498.
66. Souza JP, Boeckh M, Gooley TA, et al. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 1999; 29:1467-1471.
67. Konoplev S, Champlin RE, Giralt S, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 2001; 27:877-881.
68. Nguyen Q, Champlin R, Giralt S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999; 28:618-623.
69. Atkinson K, Nivison-Smith I, Dodds A, et al. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989. Bone Marrow Transplant 1998; 21:691-695.
70. Ghosh S, Champlin RE, Ueno NT, et al. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobu-lins. Bone Marrow Transplant 2001; 28:271-275.
71. De La Rosa GR, Jacobson KL, Rolston KV, et al. Mycobacterium tuberculosis at a comprehensive cancer centre: active disease in patients with underlying malignancy during 1990-2000. Clin Microbiol Infect 2004; 10:749-752.
72. Weinstock DM, Feinstein MB, Sepkowitz KA, Jakubowski A. High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31:1015-1021.
73. Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis 2007; 45:228-233.
74. Rano A, Agusti C, Jimenez P, et al. Pulmonary infiltrates in non-HIV immu-nocompromised patients: a diagnostic approach using noninvasive and bronchoscopic procedures. Thorax 2001; 56:379-387.
75. Wahla AS, Chatterjee A, Khan II, et al. Survey of academic pulmonologists, oncologists, and infectious disease physicians on the role of bronchoscopy in managing hematopoietic stem cell transplantation patients with pulmonary infiltrates. J Bronchol Interv Pulmonol 2014; 21:32-39.
76. Sampsonas F, Kontoyiannis DP, Dickey BF, Evans SE. Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study. Cancer 2011; 117:3424-3433.
77. Hohenadel IA, Kiworr M, Genitsariotis R, et al. Role of bronchoalveolar lavage in immunocompromised patients with pneumonia treated with a broad spectrum antibiotic and antifungal regimen. Thorax 2001; 56:115-120.
78. Rano A, Agusti C, Sibila O, Torres A. Pulmonary infections in non-HIV-immunocompromised patients. Curr Opin Pulmon Med 2005; 11:213-217.
79. White P, Bonacum JT, Miller CB. Utility of fiberoptic bronchoscopy in bone marrow transplant patients. Bone Marrow Transplant 1997; 20:681-687.
80. Shannon VR, Andersson BS, Lei X, et al. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following he-matopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45:647-655.
81. Chen SC, Kontoyiannis DP. New molecular and surrogate biomarker-based tests in the diagnosis of bacterial and fungal infection in febrile neutropenic patients. Curr Opin Infect Dis 2010; 23:567-577.
82. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67:1567-1601.
83. Rodloff C, Koch D, Schaumann R. Epidemiology and antifungal resistance in invasive candidiasis. Eur J Med Res 2011; 16:187-195.
84. Affolter K, Tamm M, Jahn K, et al. Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease. Am J Respir Crit Care Med 2014; 190:309-317.
85. Cuenca-Estrella M, Bassetti M, Lass-Florl C, et al. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011; 66 (Suppl 1):i15-i24.
86. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091-1100.
87. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265-273.
88. Maertens J, Theunissen K, Lodewyck T, et al. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 2007; 50 (Suppl 1):2-17.
89. Zedek DC, Miller MB. Use of galactomannan enzyme immunoassay for diagnosis of invasive aspergillosis in a tertiary-care center over a 12-month period. J Clin Microbiol 2006; 44:1601.
90. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005; 5:609-622.
91. Tortorano AM, Esposto MC, Prigitano A, et al. Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 2012; 50:1051-1053.
92. Huang YT, Hung CC, Hsueh PR. Aspergillus galactomannan antigenemia in penicilliosis marneffei. AIDS 2007; 21:1990-1991.
93. Wheat LJ, Hackett E, Durkin M, et al. Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol 2007; 14:638-640.
94. Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004; 42:4744-4748.
95. Vergidis P, Razonable RR, Wheat LJ, et al. Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. J Clin Microbiol 2014; 52:2199-2201.
96. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
97. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821.
98. Zou M, Tang L, Zhao S, et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One 2012; 7:e43347.
99. D'Haese J, Theunissen K, Vermeulen E, et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 2012; 50:1258-1263.
100. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417-1427.
101. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155.
102. Weissinger F, Auner HW, Bertz H, et al. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2012; 91:1161-1174.
103. von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62:341-347.
104. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus ampho-tericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415.
105. Mousset S, Buchheidt D, Heinz W, et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2014; 93:13-32.
106. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-360.
107. Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat 2005; 8:344-358.
108. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563-1571.
109. Marr K. Combination antifungal therapy: where are we now, and where are we going? Oncology (Williston Park) 2004; 18 (13 Suppl 7):24-29.
110. Reed E, Bowden R, Dandliker P, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobu-lin in patients with bone marrow transplants. Ann Intern Med 1988; 109: 783-788.
111. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109:777-782.
112. Safdar A. Immune modulatory activity of ribavirin for serious human metap-neumovirus disease: early i.v. therapy may improve outcomes in immuno-suppressed SCT recipients. Bone Marrow Transplant 2008; 41:707-708.
113. Safdar A, Hanna HA, Boktour M, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004; 101:2859-2865.
114. Safdar A, Rodriguez G, Ohmagari N, et al. The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 2005; 103:731-739.
115. Safdar A, Rodriguez GH, Lichtiger B, et al. Recombinant interferongamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006; 106:2664-2671.
116. Cherif H, Axdorph U, Kalin M, Bjorkholm M. Clinical experience of granulocyte transfusion in the management of neutropenic patients with haematological malignancies and severe infection. Scan J Infect Dis 2013; 45:112-116.
117. Bowden DH. Cell turnover in the lung. Am Rev Respir Dis 1983; 128 (2 Pt 2):S46-S48.
118. Rawlins EL, Hogan BL. Ciliated epithelial cell lifespan in the mouse trachea and lung. Am J Physiol Lung Cell Mol Physiol 2008; 295:L231-L234.
119. Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004; 23:327-333.
120. Bartlett JA, Fischer AJ, McCray PB Jr. Innate immune functions of the airway epithelium. Contrib Microbiol 2008; 15:147-163.
121. Hippenstiel S, Opitz B, Schmeck B, Suttorp N. Lung epithelium as a sentinel and effector system in pneumonia-molecular mechanisms of pathogen recognition and signal transduction. Respir Res 2006; 7:97.
122. Mayer AK, Bartz H, Fey F, et al. Airway epithelial cells modify immune responses by inducing ananti-inflammatory microenvironment. Eur J Immunol 2008; 38:1689-1699.
123. Mayer AK, Dalpke AH. Regulation of local immunity by airway epithelial cells. Arch Immunol Ther Exp 2007; 55:353-362.
124. Cleaver JO, You D, Michaud DR, et al. Lung epithelial cells are essential effectors of inducible resistance to pneumonia. Mucosal Immunol 2014; 7:78-88.
125. Clement CG, Evans SE, Evans CM, et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med 2008; 177:1322-1330.
126. Duggan JM, You D, Cleaver JO, et al. Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice. J Immunol 2011; 186:5916-5926.
127. Evans SE, Scott BL, Clement CG, et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol 2010; 42:40-50.
128. Evans SE, Tuvim MJ, Fox CJ, et al. Inhaled innate immune ligands to prevent pneumonia. Br J Pharmacol 2011; 163:195-206.
129. Evans SE, Xu Y, Tuvim MJ, Dickey BF. Inducible innate resistance of lung epithelium to infection. Annu Rev Physiol 2010; 72:413-435.
130. Moron CG, Tuvim MJ, Evans CM, Dickey BF. Stimulation of innate immune defense protects against S. pneumoniae infection [abstract]. Proc Am Thorac Soc 2005; 2:A452.
131. Tuvim MJ, Gilbert BE, Dickey BF, Evans SE. Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PLoS One 2012; 7:e30596.